Progyny (NASDAQ:PGNY) Sets New 12-Month High Following Earnings Beat

Progyny, Inc. (NASDAQ:PGNY) shares reached a new 52-week high during mid-day trading on Thursday following a stronger than expected earnings report. The stock traded as high as $35.50 and last traded at $34.0550, with a volume of 175,409 shares changing hands. The stock had previously closed at $30.10.

The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.21. The business had revenue of $341.25 million during the quarter, compared to analyst estimates of $340.76 million. Progyny had a net margin of 6.00% and a return on equity of 15.98%. Progyny’s revenue was up 8.9% compared to the same quarter last year. During the same period last year, the business earned $0.15 EPS.

Trending Headlines about Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported Q3 earnings of $0.52 per share, above analyst estimates, on revenue of $341.25 million, slightly ahead of expectations and up 8.9% year over year. The company also characterized the quarter as record-setting. Progyny Q3 results
• Positive Sentiment: The company raised its full-year 2026 earnings guidance and issued fourth-quarter guidance. A higher forecast can signal improving expectations for profitability. 2026 earnings guidance
• Positive Sentiment: Citizens raised its price target to $38 following the guidance increase, while Cantor Fitzgerald lifted its target from $31 to $35 and maintained an Overweight rating. Citizens price-target update
• Neutral Sentiment: A Q3 review highlighted new client wins and margin expansion, but described the market response as cautious—suggesting investors may want further evidence that growth and profitability will persist. Q3 business and market review

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Truist Financial boosted their price objective on shares of Progyny from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Cantor Fitzgerald boosted their price target on Progyny from $31.00 to $35.00 and gave the stock an “overweight” rating in a research note on Thursday. Weiss Ratings raised Progyny from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. KeyCorp boosted their target price on Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Finally, Barclays lowered their target price on shares of Progyny from $34.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 12th. Ten equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.92.

Insiders Place Their Bets

In other news, COO Melissa B. Cummings sold 1,879 shares of the stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $28.00, for a total value of $52,612.00. Following the transaction, the chief operating officer owned 66,496 shares in the company, valued at $1,861,888. This represents a 2.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Allison Swartz sold 3,903 shares of the stock in a transaction that occurred on Wednesday, September 23rd. The stock was sold at an average price of $26.10, for a total transaction of $101,868.30. Following the completion of the transaction, the executive vice president owned 75,816 shares in the company, valued at $1,978,797.60. This trade represents a 4.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 17,282 shares of company stock valued at $475,790. Insiders own 9.90% of the company’s stock.

Institutional Trading of Progyny

Several large investors have recently added to or reduced their stakes in PGNY. BlackRock Inc. bought a new stake in Progyny during the 2nd quarter worth approximately $334,426,000. Bank of America Corp DE boosted its position in shares of Progyny by 75.3% in the first quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock worth $20,223,000 after purchasing an additional 511,609 shares during the period. William Blair Investment Management LLC bought a new position in shares of Progyny in the second quarter worth approximately $16,807,000. Principal Financial Group Inc. boosted its position in shares of Progyny by 16.4% in the first quarter. Principal Financial Group Inc. now owns 554,916 shares of the company’s stock worth $9,422,000 after purchasing an additional 78,198 shares during the period. Finally, Danske Bank A S purchased a new stake in shares of Progyny in the second quarter worth $15,243,000. 94.93% of the stock is currently owned by institutional investors.

Progyny Stock Up 13.2%

The stock’s 50 day moving average price is $27.11 and its 200-day moving average price is $24.49. The stock has a market capitalization of $2.62 billion, a PE ratio of 37.05, a PEG ratio of 2.01 and a beta of 0.97.

Progyny Company Profile

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.